Physician profile
Steven Harvey
NPI 1811007289
$90,077.84
in general payments reported to CMS, 2019-2025
21 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,659 · 2020: $235 · 2021: $237 · 2022: $198 · 2023: $554 · 2024: $70K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Travel and Lodging: $12K · Food and Beverage: $3,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,085.00 |
| Travel and Lodging | $12,495.97 |
| Food and Beverage | $3,168.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $87,888.40 | 2019-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $773.56 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $288.93 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $221.30 | 2019-2020 | |
| Allergan, INC. | $202.85 | 2019 | |
| Axsome Therapeutics, INC. | $135.25 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $121.94 | 2025 | Cobenfy |
| Neuronetics, INC. | $78.62 | 2019 | |
| Vanda Pharmaceuticals INC. | $78.15 | 2019 | |
| Lundbeck LLC | $56.00 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $40.06 | 2019 | |
| Bausch Health US, LLC | $31.54 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $26.60 | 2025 | Spravato |
| Alkermes, INC. | $25.53 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $18.94 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalpropion Pharmaceuticals LLC | $17.40 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.71 | 2022 | |
| Amgen INC. | $15.65 | 2019 | |
| Validus Pharmaceuticals LLC | $14.03 | 2019 | |
| Neurocrine Biosciences, INC. | $13.83 | 2019 | |
| Adlon Therapeutics L.P. | $12.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.